Author:
Cheng Mu hua,Xie Liang jun
Funder
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. Younossi ZM, Wong G, Anstee QM, Henry L. The global burden of liver disease. Clin Gastroenterol Hepatol. 2023;21:1978–91.
2. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167-85.
3. Butt SRR, Satnarine T, Ratna P, Sarker A, Ramesh AS, Munoz C, et al. A systematic review on current trends in the treatment of chronic hepatitis b to predict disease remission and relapse. Cureus. 2022;14: e32247.
4. Roade L, Riveiro-Barciela M, Esteban R, Buti M. Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B. Ther Adv Infect Dis. 2021;8:2049936120985954.
5. Honkoop P, De Man RA. Entecavir: a potent new antiviral drug for hepatitis B. Expert Opin Investig Drugs. 2003;12:683–8.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献